Top

Published in:

Open Access 01-12-2015 | Research

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease

Authors: Anne Rijpma, Olga Meulenbroek, Anneke M. J. van Hees, John W. C. Sijben, Bruno Vellas, Raj C. Shah, David A. Bennett, Philip Scheltens, Marcel G. M. Olde Rikkert

Published in: Alzheimer's Research & Therapy | Issue 1/2015

Abstract

Introduction

Circulating levels of uridine, selenium, vitamins B₁₂, E and C, folate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been shown to be lower in patients with Alzheimer’s disease (AD) than in healthy individuals. These low levels may affect disease pathways involved in synapse formation and neural functioning. Here, we investigated whether, and to what extent, circulating levels of micronutrients and fatty acids can be affected by oral supplementation with Souvenaid (containing a specific nutrient combination), using data derived from three randomized clinical trials (RCT) and an open-label extension (OLE) study with follow-up data from 12 to 48 weeks.

Methods

Subjects with mild (RCT1, RCT2) or mild-to-moderate AD (RCT3) received active or control product once daily for 12–24 weeks or active product during the 24-week OLE following RCT2 (n = 212–527). Measurements included plasma levels of B vitamins, choline, vitamin E, selenium, uridine and homocysteine and proportions of DHA, EPA and total n-3 long-chain polyunsaturated fatty acids in plasma and erythrocytes. Between-group comparisons were made using t tests or non-parametric alternatives.

Results

We found that 12–24-week active product intake increased plasma and/or erythrocyte micronutrients: uridine; choline; selenium; folate; vitamins B₆, B₁₂ and E; and fatty acid levels of DHA and EPA (all p < 0.001). In the OLE study, similar levels were reached in former control product/initial active product users, whereas 24-week continued active product intake showed no suggestion of a further increase in nutrient levels.

Conclusions

These data show that circulating levels of nutrients known to be decreased in the AD population can be increased in patients with mild and mild-tomoderate AD by 24–48-week oral supplementation with Souvenaid. In addition, to our knowledge, this is the first report of the effects of sustained dietary intake of uridine monophosphate on plasma uridine levels in humans. Uptake of nutrients is observed within 6 weeks, and a plateau phase is reached for most nutrients during prolonged intake, thus increasing the availability of precursors and cofactors in the circulation that may be used for the formation and function of neuronal membranes and synapses in the brain.

Available only for authorised users

Eckert GP, Cairns NJ, Maras A, Gattaz WF, Müller WE. Cholesterol modulates the membrane-disordering effects of β-amyloid peptides in the hippocampus: specific changes in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000;11:181–6. doi:10.1159/000017234.PubMedCrossRef

Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014;20:415–8. doi:10.1038/nm.3466.PubMedCrossRef

Hartmann T, van Wijk N, Wurtman RJ, Olde Rikkert MGM, Sijben JWC, Soininen H, et al. A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer’s disease. J Alzheimers Dis. 2014;41:715–7. doi:10.3233/JAD-141137.PubMed

Morris MC. The role of nutrition in Alzheimer’s disease: epidemiological evidence. Eur J Neurol. 2009;16 Suppl 1:1–7.PubMedCentralPubMedCrossRef

Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol. 2006;63:1709–17. doi:10.1001/archneur.63.12.noc60109.PubMedCentralPubMedCrossRef

Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology. 2007;69:1921–30. doi:10.1212/01.wnl.0000278116.37320.52.PubMedCrossRef

Lopes da Silva S, Vellas B, Elemans S, Luchsinger J, Kamphuis P, Yaffe K, et al. Plasma nutrient status of patients with Alzheimer’s disease: systematic review and meta-analysis. Alzheimers Dement. 2014;10:485–502. doi:10.1016/j.jalz.2013.05.1771.PubMedCrossRef

Cardoso BR, Ong TP, Jacob-Filho W, Jaluul O, d’Ávila Freitas MI, Cozzolino SMF. Nutritional status of selenium in Alzheimer’s disease patients. Br J Nutr. 2010;103:803–6. doi:10.1017/s0007114509992832.PubMedCrossRef

Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging. 2003;24:915–9. doi:10.1016/S0197-4580(03)00031-9.PubMedCrossRef

10.

Olde Rikkert MG, Verhey FR, Sijben JW, Bouwman FH, Dautzenberg PL, Lansink M, et al. Differences in nutritional status between very mild Alzheimer’s disease patients and healthy controls. J Alzheimers Dis. 2014;41:261–71. doi:10.3233/JAD-131892.PubMed

11.

van Wijk N, Broersen LM, de Wilde MC, Hageman RJ, Groenendijk M, Sijben JW, et al. Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination. J Alzheimers Dis. 2014;38:459–79. doi:10.3233/JAD-130998.PubMed

12.

Wurtman RJ. A nutrient combination that can affect synapse formation. Nutrients. 2014;6:1701–10. doi:10.3390/nu6041701.PubMedCentralPubMedCrossRef

13.

Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr. 2009;29:59–87. doi:10.1146/annurev-nutr-080508-141059.PubMedCrossRef

14.

Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging. 2011;15:720–4.PubMedCrossRef

15.

Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement. 2010;6:1–10.e1. doi:10.1016/j.jalz.2009.10.003.PubMedCrossRef

16.

Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012;31:225–36. doi:10.3233/JAD-2012-121189.PubMed

17.

Olde Rikkert MGM, Verhey FR, Blesa R, von Arnim CAF, Bongers A, Harrison J, et al. Tolerability and safety of Souvenaid in patients with mild Alzheimer’s disease: results of multi-center, 24-week, open-label extension study. J Alzheimers Dis. 2015;44:471–80. doi:10.3233/jad-141305.PubMed

18.

Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease. Alzheimers Res Ther. 2013;5:59. doi:10.1186/alzrt224.PubMedCentralPubMedCrossRef

19.

Olde Rikkert MGM, Verhey FR, Blesa R, von Arnim CAF, Bongers A, Harrison J, et al. Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study. J Alzheimers Dis. 2014. doi:10.3233/jad-141305.

20.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMedCrossRef

21.

Directive 2008/100/EC on nutritional labelling for foodstuffs as regards recommended daily allowances, energy conversion factors and definitions.

22.

U.S. Food and Drug Administration. Guidance for Industry: A Food Labeling Guide.

23.

Fossati T, Colombo M, Castiglioni C, Abbiati G. Determination of plasma choline by high-performance liquid chromatography with a postcolumn enzyme reactor and electrochemical detection. J Chromatogr B Biomed Appl. 1994;656:59–64.PubMedCrossRef

24.

van Wijk N, Watkins CJ, Böhlke M, Maher TJ, Hageman RJ, Kamphuis PJ, et al. Plasma choline concentration varies with different dietary levels of vitamins B₆, B₁₂ and folic acid in rats maintained on choline-adequate diets. Br J Nutr. 2012;107:1408–12. doi:10.1017/S0007114511004570.PubMedCrossRef

25.

Catignani GL. An HPLC method for the simultaneous determination of retinol and α-tocopherol in plasma or serum. Methods Enzymol. 1986;123:215–9.PubMedCrossRef

26.

Kuo K, Still R, Cale S, McDowell I. Standardization (external and internal) of HPLC assay for plasma homocysteine. Clin Chem. 1997;43:1653–5.PubMed

27.

Krijt J, Vacková M, Kožich V. Measurement of homocysteine and other aminothiols in plasma: advantages of using tris(2-carboxyethyl)phosphine as reductant compared with tri-n-butylphosphine. Clin Chem. 2001;47:1821–8.PubMed

28.

Fukunaga K, Yoshida M, Nakazono N. A simple, rapid, highly sensitive and reproducible quantification method for plasma malondialdehyde by high-performance liquid chromatography. Biomed Chromatogr. 1998;12:300–3. doi:10.1002/(SICI)1099-0801(199809/10)12:5<300::AID-BMC751>3.0.CO;2-##.PubMedCrossRef

29.

Wynants J, Van Belle H. Single-run high-performance liquid chromatography of nucleotides, nucleosides, and major purine bases and its application to different tissue extracts. Anal Biochem. 1985;144(85):258–66. doi:0003-2697(85)90114-9.PubMedCrossRef

30.

Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497–509.PubMed

31.

Kolarovic L, Fournier NC. A comparison of extraction methods for the isolation of phospholipids from biological sources. Anal Biochem. 1986;156:244–50. doi:0003-2697(86)90179-X.PubMedCrossRef

32.

Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7.PubMedCrossRef

33.

Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride–methanol. J Lipid Res. 1964;5:600–8.PubMed

34.

Carr AC, Bozonet SM, Vissers MC. A randomised cross-over pharmacokinetic bioavailability study of synthetic versus kiwifruit-derived vitamin C. Nutrients. 2013;5:4451–61. doi:10.3390/nu5114451.PubMedCentralPubMedCrossRef

35.

Jeanes YM, Hall WL, Lodge JK. Comparative ²H-labelled α-tocopherol biokinetics in plasma, lipoproteins, erythrocytes, platelets and lymphocytes in normolipidaemic males. Br J Nutr. 2005;94:92–9.PubMedCrossRef

36.

Gibellini F, Smith TK. The Kennedy pathway—de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life. 2010;62:414–28. doi:10.1002/iub.337.PubMedCrossRef

37.

Cansev M, Wurtman RJ, Sakamoto J, Ulus IH. Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimers Dement. 2008;4(1 Suppl 1):S153–68. doi:10.1016/j.jalz.2007.10.005.PubMedCentralPubMedCrossRef

38.

Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, et al. Plasma metabolite profiles of Alzheimer’s disease and mild cognitive impairment. J Proteome Res. 2014;13:2649–58. doi:10.1021/pr5000895.PubMedCrossRef

39.

Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics. PLoS One. 2013;8, e63644. doi:10.1371/journal.pone.0063644. PONE-D-13-05431.PubMedCentralPubMedCrossRef

40.

Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V, et al. Metabolite profiling of Alzheimer’s disease cerebrospinal fluid. PLoS One. 2012;7, e31501. doi:10.1371/journal.pone.0031501.PubMedCentralPubMedCrossRef

41.

Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case–control study. Br J Nutr. 2003;89:483–9.PubMedCrossRef

42.

Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One. 2010;5, e12538. doi:10.1371/journal.pone.0012538.PubMedCentralPubMedCrossRef

43.

Selley ML. A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer’s disease. Neurobiol Aging. 2007;28:1834–9. doi:10.1016/j.neurobiolaging.2006.08.003.PubMedCrossRef

44.

Jessen F, Gür O, Block W, Ende G, Frölich L, Hammen T, et al. A multicenter ¹H-MRS study of the medial temporal lobe in AD and MCI. Neurology. 2009;72:1735–40. doi:10.1212/WNL.0b013e3181a60a20.PubMedCrossRef

45.

van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Hoefnagels WH, Beekman ATF, et al. Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2008;88:706–13.PubMed

46.

Vedin I, Cederholm T, Freund Levi Y, Basun H, Garlind A, Faxén Irving G, et al. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr. 2008;87:1616–22.PubMed

47.

Buchman AL, Sohel M, Brown M, Jenden DJ, Ahn C, Roch M, et al. Verbal and visual memory improve after choline supplementation in long-term total parenteral nutrition: a pilot study. JPEN J Parenter Enteral Nutr. 2001;25:30–5. doi:10.1177/014860710102500130.PubMedCrossRef

48.

Thal LJ, Rosen W, Sharpless NS, Crystal H. Choline chloride fails to improve cognition of Alzheimers disease. Neurobiol Aging. 1981;2:205–8. doi:10.1016/0197-4580(81)90022-1.PubMedCrossRef

49.

Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A. 1992;89:1671–5.PubMedCentralPubMedCrossRef

50.

Kosicek M, Hecimovic S. Phospholipids and Alzheimer’s disease: alterations, mechanisms and potential biomarkers. Int J Mol Sci. 2013;14:1310–22. doi:10.3390/ijms14011310.PubMedCentralPubMedCrossRef

51.

Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007;1182:50–9. doi:10.1016/j.brainres.2007.08.089.PubMedCentralPubMedCrossRef

52.

Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxén-Irving G, Vedin I, et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study. Dement Geriatr Cogn Disord. 2009;27:481–90. doi:10.1159/000218081.PubMedCrossRef

53.

Lloret A, Badía MC, Mora NJ, Pallardó FV, Alonso MD, Viña J. Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis. 2009;17:143–9. doi:10.3233/JAD-2009-1033.PubMed

54.

Cornelli U. Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener Dis. 2010;7:193–202. doi:10.1159/000295663.PubMedCrossRef

55.

van Wijk N, Watkins CJ, Hageman RJJ, Sijben JWC, Kamphuis PJGHJ, Wurtman RJ, et al. Combined dietary folate, vitamin B-12, and vitamin B-6 intake influences plasma docosahexaenoic acid concentration in rats. Nutr Metab (London). 2012;9:49. doi:10.1186/1743-7075-9-49.CrossRef

56.

Zerbi V, Jansen D, Wiesmann M, Fang X, Broersen LM, Veltien A, et al. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer’s disease. Neurobiol Aging. 2014;35:600–13. doi:10.1016/j.neurobiolaging.2013.09.038.PubMedCrossRef

57.

Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of α-linolenic acid metabolism in young men. Br J Nutr. 2002;88:355–63. doi:10.1079/bjn2002662.PubMedCrossRef

58.

Burdge GC, Wootton SA. Conversion of α-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr. 2002;88:411–20. doi:10.1079/bjn2002689.PubMedCrossRef

59.

Flock MR, Skulas-Ray AC, Harris WS, Etherton TD, Fleming JA, Kris-Etherton PM. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose–response randomized controlled trial. J Am Heart Assoc. 2013;2, e000513. doi:10.1161/JAHA.113.000513.PubMedCentralPubMedCrossRef

60.

Kim HY. Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem. 2007;282:18661–5. doi:10.1074/jbc.R700015200.PubMedCrossRef

61.

Cohen EL, Wurtman RJ. Brain acetylcholine: control by dietary choline. Science. 1976;191:561–2.PubMedCrossRef

62.

Umhau JC, Zhou W, Carson RE, Rapoport SI, Polozova A, Demar J, et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res. 2009;50:1259–68. doi:10.1194/jlr.M800530-JLR200.PubMedCentralPubMedCrossRef

63.

Cansev M, Watkins CJ, van der Beek EM, Wurtman RJ. Oral uridine-5′-monophosphate (UMP) increases brain CDP-choline levels in gerbils. Brain Res. 2005;1058:101–8. doi:10.1016/j.brianres.2005.07.054.PubMedCrossRef

64.

de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJGH, Scheltens P, et al. The effect of Souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study. PLoS One. 2014;9, e86558. doi:10.1371/journal.pone.0086558.PubMedCentralPubMedCrossRef

65.

Rijpma A, Meulenbroek O, van der Graaf M, Lansbergen M, de Wilde M, Heerschap A, et al. Rationale and design of an MRS study to explore the effects of the medical food Souvenaid® on brain metabolites in Alzheimer’s disease [abstract P4-263]. Alzheimers Dement. 2013;9(4):801. doi:10.1016/j.jalz.2013.05.1656.CrossRef

Title: Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Authors: Anne Rijpma
Olga Meulenbroek
Anneke M. J. van Hees
John W. C. Sijben
Bruno Vellas
Raj C. Shah
David A. Bennett
Philip Scheltens
Marcel G. M. Olde Rikkert
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Alzheimer's Research & Therapy / Issue 1/2015
Electronic ISSN: 1758-9193
DOI: https://doi.org/10.1186/s13195-015-0134-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly

Kidney disease as a determinant of cognitive decline and dementia

Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study

Cumulative impact of health deficits, social vulnerabilities, and protective factors on cognitive dynamics in late life: a multistate modeling approach

Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study

Clinical and imaging features of mixed Alzheimer and vascular pathologies